Maternal mortality remains disproportionately high in low-income and middle-income countries, where pyramidal health systems ...

The University of Professional Studies, Accra (UPSA), has officially launched a Doctor of Philosophy (PhD) in Public Policy and Leadership, alongside three new Applied Statistics programmes as part of ...

Primary and secondary outcome measures Children’s mental health was assessed using the Mental Health Test; parental anxiety and depression were measured with the Generalised Anx ...

So, you’re looking to get a handle on cyber security, eh? It can feel a bit overwhelming with all the technical bits and bobs ...

Read out expert’s BOYLE Sports review as we offer insightful, in-depth analysis on all their sportsbook has to offer in ...

The rise of artificial intelligence has led to the creation of neoclouds -- companies that specialize in operating data centers designed to power AI. Neocloud CoreWeave rents data center space from ...

Shares of digital infrastructure provider Applied Digital (NASDAQ:APLD) jumped 2.8% in the morning session after the company announced it had broken ground on a new artificial intelligence (AI) data ...

Shares of digital infrastructure provider Applied Digital (NASDAQ:APLD) jumped 4.8% in the afternoon session after investor optimism grew on the back of its strong growth pipeline, a substantial order ...

CoreWeave and Applied Digital both had strong performances in 2025. Demand for CoreWeave's AI cloud services is through the roof. Applied Digital, meanwhile, is providing the specialized buildings and ...

Applied Materials faces headwinds from reduced China exposure and cyclical weakness in key segments, tempering recent growth. 2026 is expected to favor AMAT’s strengths, with leading-edge ...

Applied Digital Corp (NASDAQ: APLD) shares are trending on Monday. Here’s a look at what you need to know. What To Know: Applied Digital has shifted its primary focus from hosting Bitcoin mining ...

Cycle Pharmaceuticals is circling up Applied Therapeutics, acquiring the rare disease biotech after an extremely tumultuous year for the latter that began with an FDA rejection at the end of 2024.